USPTO Upholds Santaris Pharma A/S Patents in Two Reexamination Cases Brought by Isis Pharmaceuticals
- Sterne, Kessler, Goldstein & Fox
Sterne Kessler client Santaris Pharma A/S announces it has won two significant patent reexamination cases brought by Isis Pharmaceuticals.
The positive rulings by the United States Patent and Trademark Office (USPTO) cover two key Santaris Pharma A/S "Imanishi" patents – U.S. Pat. No. 6,268,490 (the '490 patent) and U.S. Pat. No. 6,770,748, (the '748 patent) – which claim rights to the Locked Nucleic Acid (LNA) or Bicyclic Nucleic Acid (BNA) chemical structure used for developing antisense molecules. The USPTO revoked the ex parte reexamination of the '490 patent and provided a Notice of Intent to Issue a Reexamination Certificate that confirms the patentability of all claims of the '490 patent co-owned by Santaris Pharma A/S and is not subject to appeal. In addition, the USPTO issued an Action Closing Prosecution in the inter-partes reexamination of '748 patent, which is a continuation-in-part of the ‘490 patent, confirming all of the original claims.
The Santaris Pharma A/S patent reexamination team is led by Eric K. Steffe and John M. Covert of Sterne, Kessler, Goldstein & Fox, P.L.L.C.